Table 2.
Patient characteristics.
| Patients with MM (n = 32) | ||
| Gender | Female | 51.4% |
| Male | 48.6% | |
| Mean age | 68 years (38–86 years) | |
| Clinical stage (Durie & Salmon) | IA | 10.8% |
| IB | 0% | |
| IIA | 13.5% | |
| IIB | 5.4% | |
| IIIA | 18.9% | |
| Clinical stage (ISS) | I | 13.5% |
| II | 13.5% | |
| III | 70.0% | |
| Patients with NHL-DLBCL (n = 34) | ||
| Gender | Female | 47.1% |
| Male | 52.9% | |
| Mean age | 60.4 years (38–82 years) | |
| Clinical stage (Ann Arbor) | IA | 11.8% |
| IB | 2.9% | |
| IIA | 8.8% | |
| IIB | 11.8% | |
| IIBs | 2.9% | |
| IIIA | 8.8% | |
| IIIB | 23.5% | |
| IIIBs | 2.9% | |
| IVB | 14.7% | |
| Extranodal involvement | Yes | 44.1% |
| No | 55.9% | |
| “В” symptoms | Yes | 41.3% |
| No | 58.7% | |
| Patients with CLL (n = 32) | ||
| Gender | Female | 34.4% |
| Male | 65.6% | |
| Mean age | 68 years (45–90 years) | |
| Clinical stage (Rai) | 0 | 3.1% |
| I | 43.8% | |
| II | 37.5% | |
| III | 6.3% | |
| IV | 9.4% | |
| Clinical stage (Binet) | A | 62.5% |
| B | 25.0% | |
| C | 12.5% |